Peptide

AOD-9604: How It Works, What It's Studied For & Safety

Quick answer

AOD-9604 is a 16-amino-acid fragment of human growth hormone studied for its effect on lipolysis without the broader anabolic signaling of full-length GH. Clinicians consider it for adipose-tissue research and body-composition support. Not FDA-approved; dispensed by Wells Pharmacy Network only after a clinician evaluation.

Also known as: Lipotropin Fragment 176-191, AOD9604

How does AOD-9604 work?

AOD-9604 corresponds to amino acids 176-191 of the C-terminus of human growth hormone. Preclinical work shows it engages adipocyte beta-3 adrenergic signaling and is studied for its effect on lipolysis and lipogenesis without binding the GH receptor in the same way the full molecule does. Because it does not measurably raise IGF-1, clinicians sometimes consider it as a non-anabolic adjunct in body-composition protocols.

What is AOD-9604 studied for?

  • Adipose-tissue research and body-composition support
  • Pairing with GHRH/GHRP peptides in clinician-directed metabolic protocols
  • Appetite-neutral fat-metabolism research where IGF-1 elevation is undesired

How is AOD-9604 taken?

Most commonly compounded as a daily subcutaneous injection. Some clinicians use it in cycled blocks alongside MOTS-c or AOD-paired GLP-1 protocols.

Is AOD-9604 FDA-approved? Is it safe?

Not FDA-approved for the prevention, treatment, or cure of any condition. Used inside research-informed, clinician-directed protocols only. Compounded prescription-only preparations are dispensed by Wells Pharmacy Network. Eligibility is decided by a licensed clinician based on intake and labs, not by checkout. Compounded products on this site are not FDA-approved and are not generic equivalents of any branded medication.

In the Regen Therapy catalog

The protocols below are dispensed by Wells Pharmacy Network and contain AOD-9604. Each one is prescribed only after a clinician evaluation.

What does the research say about AOD-9604?

Early human and animal pharmacology was published in the 2000s. AOD-9604 received GRAS status as a food ingredient in 2014 from an industry sponsor - a separate regulatory pathway from a drug approval. No phase-3 weight-loss trials have established efficacy as a finished medication.

Considering AOD-9604 as part of a protocol?

Browse Regen Therapy's catalog or start a clinician evaluation. Every prescription is reviewed by a licensed clinician and dispensed by Wells Pharmacy Network.

Browse the catalog →

Compare AOD-9604 with similar protocols